news

Transfer of oncogene in colon cancer cells demonstrated

Posted: 22 July 2019 | | No comments yet

A new study has shown that proteins derived from the oncogene, KRAS, can transfer between colon cancer cells.

Dr Emil Lou and his research team have demonstrated that proteins derived from the oncogene KRAS have the ability to transfer between colon cancer cells via long cellular skyway-like extensions called ‘tunneling nanotubes’. According to the researchers, inhibiting these signals may be a target for treatment. 

The oncogene, KRAS, is implicated in driving cancer, including its origin and growth patterns in 30 percent of all cancers and contributes to tumours becoming drug-resistant. The study examined what happens when a normal form of the protein mutates. The researchers found that the transfer of KRAS caused the surrounding cells to behave in a more cancerous, invasive manner that is more likely to be resistant to standard drugs.

“Most aggressive metastatic colon tumours in patients will develop drug resistance. It’s not a matter of ‘if’, but a matter of ‘when’ for most patients and that’s a big challenge in this field,” said Dr Lou, Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School. “We speculate that cutting off the line of communication for transfer of vital signals might be a novel therapeutic strategy in addition to standard-of-care chemotherapy.”

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

The researchers hope that these findings will help devise better recognition of ways to revise clinical trial strategies to overcome biological resistance at the cellular level. “This study opens new avenues to fully understand the effects of the transfer of KRAS in colon and other similar cancers driven by KRAS,” Dr Lou continued.

Research into the next steps also will entail figuring out how to cut off that communication.

The study was published in Cancers.

Related conditions

Related people

Leave a Reply

Your email address will not be published. Required fields are marked *